Filing Details
- Accession Number:
- 0000899243-22-034368
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2022-10-27 21:23:03
- Reporting Period:
- 2022-09-13
- Accepted Time:
- 2022-10-27 21:23:03
- Original Submission Date:
- 2022-09-15
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1744659 | Akero Therapeutics Inc. | AKRO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1779479 | Timothy Rolph | C/O Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-09-13 | 10,000 | $6.36 | 256,337 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-09-13 | 22,500 | $29.18 | 233,837 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-09-13 | 10,000 | $0.00 | 10,000 | $6.36 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 62,756 | 2029-01-15 | No | 4 | M | Direct |
Footnotes
- On September 15, 2022, the reporting person filed a Form 4 which inadvertently omitted the exercise of 10,000 options by the reporting person. The shares of Common Stock underlying those options were subsequently sold pursuant to a Rule 10b5-1 trading plan as reported in the original Form 4. This amendment to the original Form 4 is being filed solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock.
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2021, previously adopted by the reporting person.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- This option shall vest and become exercisable in 48 equal monthly installments, commencing on January 1, 2019.
Billionaire Hedge Funds
